Developing a Statistical Plan/ Objectives pertaining to “Safety”

Jordan Elm
Medical University of South Carolina
AAN CME Disclosure

- Dr. Elm has **no commercial or financial interests to disclose** related to this talk.

- This presentation **will not include** information on unlabeled use of any commercial products or investigational use that is not yet approved for any purpose.
SPECIFIC AIMS

1. To demonstrate that MYDRUG is better than control at improving outcome.
2. To demonstrate that MYDRUG is safe.
What is wrong with these SPECIFIC AIMS?
SPECIFIC AIMS

1. To demonstrate that MYDRUG is better than control at improving outcome.
2. To demonstrate that MYDRUG is safe.

Clinical Equipoise??

Hard to prove, especially with small sample...
What is wrong with these SPECIFIC AIMS?

- Hard to prove drug is “safe”
  - Failure to reject the null hypothesis, does not imply that the null is true.
  - “No safety concerns were identified.”
Safety Hypotheses

- Specific Aims/Objectives need to state the outcome/endpoint *(what you are measuring, be specific).*

- “Safety” is not an outcome.

- Focus “identify harms”, not “prove safety”.
Safety Hypotheses

- Unlike efficacy hypotheses, safety hypotheses often can’t be pre-specified due to the exploratory nature.

- Most trials are not designed to detect differences in safety outcomes btw groups. Sample size based on efficacy.

- Commonly, not enough power to detect rare adverse events.
Phase I designs : CRM or 3+3

- Historically phase I designed to ID MTD. cancer drug=toxicity at a high frequency (30%)
- May not work well for other areas (prevention or long term use) where 30% event rate is unacceptable.
Safety through the Life cycle of the drug development

- Assessment of safety is ongoing, not just a Phase I or Phase II trial objective.
- Phase IV trials/ post-marketing surveillance to continue to monitor for safety concerns
- Sometimes safety concerns are not detected until drug comes to market: Celebrex
How much do we already know? (Dig Deep)

- New medicinal product or a marketed product
- Early, middle, or late stage trial?
- What is target/Mechanism of Action?
- Are there events that we can anticipate based on this?
Know what is Expected

- Investigator’s brochure– gives rates of expected AEs
- Other studies of drug in other disease areas.
- Be mindful of what is expected due to disease alone versus drug/device
  - Edema expected with Pioglitazone 6% diabetes
  - PD study observed 12% edema rate (edema more common in PD).
Know What is Expected with the Control Group

- If you expect an event based on target, but have no idea what rate then......
- Use epidemiological or natural history data to determine anticipated rate in the control group.
- Control group from another study of similar patients.
How much can the rate increase?

- Given expected rate, what increase in the event rate would be medically concerning?
- Relative risk of 3 or more **
- Use this to define your safety analyses.

Risk/Benefit Ratio

- Cancer – accept a high toxicity rate in the short term
- Prevention of disease (recurrent stroke),
  - long term use
  - baseline risk of disease is low or moderate
  - don’t want to cause other major problems
- Alzheimer's- if we can delay degeneration, may accept other AEs.
Tolerability

- Related to safety, but slightly different.

- If 30% of patients stop taking the drug due to minor side effects, then you may have a tolerability issue.

- Is my drug tolerable? Defined as <10% patients stopped/reduced dose of assigned drug due to any AE.
Tolerability/Compliance

What % of assigned dose was taken?
- Ascertainment issues
- Pill count
- Dose reductions, start/stop/re-start
  (days on drug/days expected to be on drug excluding deaths)
- Device use (electronic)
Safety/Tolerability Objectives

- Safety Objective
  - Identify if intervention harmful (not proving safe)

- Tolerability objective
  - 80-90% of patients complete study on assigned dose (prevention or long-term use)
Safety Aim: Identify if intervention harmful

1. Anticipate potential harms
2. Define a Primary Safety Outcome (composite of several potential events if appropriate)
3. Determine Expected Rates (drug/control group)
4. Define Clinically worrisome increase?
Measuring “Safety”
Adverse Event reports

- “‘any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related’”*

- Collection of AEs is passive,
  - *What unusual symptoms or medical problems have you experienced since last visit….

*[21 CFR 312.32 (a)]
Adverse Events

- Record all events after randomization regardless of relatedness
- Centrally coded (MedDRA)

- Coded AEs can be grouped by
  - Body System (SOC) → Preferred Term (PT)
- Cumulative occurrence rate by treatment group reported to DSMB
<table>
<thead>
<tr>
<th>Body System</th>
<th>MedDRA Preferred Term</th>
<th>A</th>
<th>B</th>
<th>C</th>
<th>Total A</th>
<th>Total B</th>
<th>Total C</th>
<th>A % of Subj</th>
<th>B % of Subj</th>
<th>C % of Subj</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood and lymphatic system disorders</td>
<td>Anaemia</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>3</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>Thrombocytopenia</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Cardiac disorders</td>
<td>Atrial fibrillation</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>Atrial flutter</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Ear and Labyrinth Disorders</td>
<td>Tinnitus</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>Vertigo</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Endocrine disorders</td>
<td>Hypothyroidism</td>
<td>0</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>Gastrointestinal disorders</td>
<td>Abdominal discomfort</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Abdominal pain</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>Constipation</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>3</td>
<td>0</td>
<td>0</td>
<td>5</td>
</tr>
<tr>
<td></td>
<td>Diarrhoea</td>
<td>0</td>
<td>1</td>
<td>6</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>Dyspepsia</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1</td>
</tr>
</tbody>
</table>
Issues with MedDRA Codes

Wittes, Crowe, et al. Statistics in Biopharmaceutical Research: August 2015

- A single event may get reported as individual symptoms and signs (multiple AEs)
- Body System—too broad
- Preferred Term – similar events get grouped into different PT and SOC
  - “pulmonary edema” → Respiratory SOC
  - “heart failure” → Cardiovascular SOC
  - same medical condition.

- Hard to detect safety issues!
“Group” Safety Events

- Be consistent with data collection
  - Make sure to consistently report the diagnosis (not signs and symptoms)
- Use Composites
  - Group major safety events so that the signal is not diluted.
  - Group efficacy and safety outcomes to look at the global effect of the treatment
- Group “near” terms
  - Nausea/Vomiting/Dyspepsia
  - Skin reaction/Rash
  - Increased Blood urea/Increased Creatinine/renal failure
- Higher Level Terms (MEDdra)
If similar terms are separated, Signal is diluted

<table>
<thead>
<tr>
<th>MedDRA PT</th>
<th>Treatment</th>
<th>Control</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abdominal discomfort</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Abdominal pain</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Constipation</td>
<td>5</td>
<td>2</td>
</tr>
<tr>
<td>Diarrhoea</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td><strong>8</strong></td>
<td><strong>2</strong></td>
</tr>
</tbody>
</table>
Prospectively collect

- If you specifically ask about it, you will get better ascertainment than recall
- Only possible for anticipated or expected events (not rare, unexpected)
- “Cleaner” data
- A well-defined prospective definition is better than a central adjudication team
  - Only as good as what gets initially reported.
Ischemic stroke: An acute focal infarction of the brain or retina (and does not include anterior ischemic optic neuropathy (AION)). Criteria: (1) Rapid onset of a new focal neurological deficit with clinical or imaging evidence of infarction and not attributable to a non-ischemic etiology (not associated with brain infection, trauma, tumor, seizure, severe metabolic disease, or degenerative neurological disease); or, (2) Rapid worsening of an existing focal neurological deficit that is judged by the Investigator to be attributable to a new infarction. Criteria for symptoms attributable to new infarction may include symptoms that persist and are judged by the investigator to be attributable to new infarction, imaging evidence of infarction or no evidence of a non-ischemic etiology.

TIA: A neurological deficit of sudden onset, resolving completely, attributed to focal brain or retinal ischemia without evidence of associated acute focal infarction of the brain. Criteria: rapid onset of a focal neurological deficit that is without evidence of acute focal infarction of the brain, and is not attributable to a non-ischemic etiology (brain infection, trauma, tumor, seizure, severe metabolic disease, or degenerative neurological disease).

Symptomatic hemorrhagic transformation of an ischemic stroke: Any extravascular blood within an area of known acute/subacute infarction which is judged to be nontraumatic, and responsible for neurologic symptoms. To be considered symptomatic, the hemorrhagic transformation must be judged to be partially responsible for the subject's clinical neurologic presentation (i.e., the area of Infarction is not adequate to explain the neurologic deficit, or a secondary neurologic deterioration occurred corresponding to the timing of hemorrhagic transformation). Criteria (must meet both of the following):
   a. Imaging evidence (by CT or MR) of extravascular blood within the area of infarction.
   b. Symptoms judged to be related to the hemorrhagic transformation. Scenarios which may be judged as symptomatic: (i) If blood is already present on imaging at presentation, symptoms are out of proportion to what would be expected for the size and location of the infarct at presentation; (ii) Clinical deterioration, defined by an increase of 4 points or more in the score on the NIHSS or leading to death, occurring after the initial ischemic event, and identified as the result of the hemorrhagic transformation; or (iii) Mass effect secondary to the hemorrhagic transformation causing symptoms.

Asymptomatic hemorrhagic transformation of an ischemic stroke: Any extravascular blood within an area of known acute/subacute infarct, judged to be nontraumatic, without any related neurologic symptoms. Criteria (must meet both of the following):
   a. Imaging evidence (by CT or MRI) of extravascular blood within the area of infarct.
   b. No symptoms related to the hemorrhagic transformation, or clinical deterioration with less than a 4-point increase in score on the NIHSS judged to be related to the hemorrhagic transformation.

Symptomatic intracerebral hemorrhage: Any extravascular blood in the brain parenchyma, judged to be nontraumatic, and not in the area of an acute/subacute ischemic infarct, associated with and identified as the predominant cause of new neurologic symptoms (including headache) or death. In the case of a mixed intracranial hemorrhage [Intracerebral Hemorrhage (ICH), Subarachnoid Hemorrhage (SAH), Subdural Hemorrhage (SDH), and/or Intraventricular Hemorrhage (IVH)], the event should be classified according to the primary site of hemorrhage by the judgment of the clinician. For example, if 50% or more of the intracerebral blood is located in the intraventricular space, the classification would be Intraventricular Hemorrhage (IVH).
Serious Adverse Event (SAE)

- An adverse event is an SAE if it meets FDA definition
  - Fatal
  - Life-Threatening
  - Result in hospitalization/prolonged hospitalization
  - Result in disability/congenital anomaly
  - Require intervention to prevent permanent impairment or damage
  - Other Important Medical Event

- Don’t just look at SAEs! Related events may not always result in an SAE.
IRBs, FDA have reporting guidelines.
- Unexpected, Serious Adverse Reaction should be reported within 15 days, etc.
- Difficult for FDA to determine causality

Only the DSMB sees aggregate data by treatment
Who is Watching safety in ongoing trial?

- Investigator-patient level
- Clinical monitor-several sites
- Medical Monitor at the Sponsor or Coordination Center (blinded data, one at a time)
- FDA/EMEA (annual reports, SAEs in real time)
- IRB-Serious adverse events at local site
- Only the DSMB sees aggregate data by treatment
Monitoring plan

- Safety Monitoring Plan
- Statistical Analysis Plan
- DSMB Monitoring Plan
- Formal plan pre-specifying what interim data are to be monitored and how
- Procedures for reporting AEs/SAEs to DSMB (FDA, IRB)
- Expected Adverse Events Rates
DSMB Monitoring Plan

Should clearly describe the details of the proposed plan for interim data monitoring:

- What data will be monitored? (Endpoints, AEs)
- The timing of all interim analyses?
- The frequency of data reviews.
- Criteria that will guide early termination
  (Stopping Rules)
Should the DSMB Know which Treatment Group is which?

• Unlike IRB, FDA, Study PI, only DSMB sees safety data aggregated by treatment group
• Initial DSMBs are often “partially blinded”
  – code treatment (A or B)
• DSMB should be unblinded when appropriate:
  – have a sealed envelope with codes to be opened when DSMB requests.
Safety Analysis
Safety Analysis Sample

- Include anyone who received the study drug, but only while they were on the drug (person-years or Risk Set).
- If didn’t get the drug, then they can’t be harmed by it. Don’t use an Intent-to-Treat (ITT) sample.
- Cross-overs should analyze according to what they actually received.
Safety Aim: Identify if intervention harmful

1. Anticipate potential harms
2. Define a Primary Safety Outcome (composite of several potential events if appropriate)
3. Determine Expected Rates (drug/control group)
4. Define Clinically worrisome increase?
5. Consider Sample Size
Sample Size for primary safety outcome

- Two group comparison?
  $H_0$: treatment=control vs $H_A$: treatment≠control

- One or Two sided test? Reject null if treatment worse than control

- But for rare events or a small increase in event rates, we may fail to reject the null hypothesis.
Safety Analysis

- One or two sample test
- Confidence Intervals around effect size
- Frequency of Events (%)
  - Relative Risk (ratio) $p_A/p_B$
  - Absolute Risk Difference $p_A-p_B$
  - Odds Ratio $p_A/(1-p_A)/p_B/(1-p_B)$
- Hazard Ratio (time to event)
- Adjust for baseline covariates
  - Logistic Regression
  - Log Binomial model
  - Cox PH
Multiple “Looks” at the data

- Will increase the likelihood of finding a statistically significant difference even if none exists
- Repeated tests → increase Type I error
- Group Sequential / Alpha-spending functions are statistical tools to protect the type I error rate (primary outcome)
Random High: CHARM program
(Pocock et al, Am Heart J 2005)
Adjust for Multiple Comparisons?

- Not trying to PROVE safety, just quantify risks, so multiplicity is less of a concern
- Worry about inflating the type I error rate (false positive rate), but not too much (uniform p-value=0.01)
Identifying harms

- Look frequently at safety data.

- Often difficult to define formal boundaries for safety but can set boundaries based on reversed efficacy.

- Boundaries can depend on experience with the new treatment.
Stopping Rules

- Decide if formal stopping rules for safety are needed
  - Expected AE (3% sICH), know increase that would be concerning (6% sICH).
- State in advance.
- Rules are guidelines: stopping is not mandatory.
- Monitoring requires a combination of statistical and clinical insights.
- Stop if interim data suggest trial poses an unreasonable risk to participants.
### AEs potentially related: monitored for trend

<table>
<thead>
<tr>
<th>SAFETY EVENT</th>
<th>TRT GROUP</th>
<th>Expected event rate</th>
<th># AT RISK</th>
<th># EVENTS</th>
<th>EVENT PROPORTION (%)</th>
<th>RR</th>
<th>RR 95% CI</th>
<th>OBS TIME</th>
<th>EVENT RATE</th>
<th>EVENT RATE 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>DEATH</td>
<td>A</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>B</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td></td>
<td></td>
<td>3%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>INTRACRANIAL HEMORRHAGES</td>
<td>A</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>B</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td></td>
<td></td>
<td>0.5%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MAJOR HEMORRHAGE</td>
<td>A</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>B</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td></td>
<td></td>
<td>2%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MINOR HEMORRHAGE</td>
<td>A</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>B</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td></td>
<td></td>
<td>2%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Expected Event rate:** the rate observed in treated patients from pilot cohort studies.
**# at risk:** the number of subjects who have passed the timepoint or had safety event
**# events:** the number of subjects who have experienced the safety event
**Event proportion:** (# events)/(# at risk).
**Observed time:** the sum of the person-time available for each subject.
**Event rate:** (# events)/(observed time)
Probability of observing this many events given true rate (binomial CDF)

<table>
<thead>
<tr>
<th>Treatment Group</th>
<th>Subgroup Age</th>
<th>X Number of Subjects with sICH</th>
<th>N</th>
<th>% of subjects</th>
<th>Probability of observing X or more given true rate is 3%</th>
<th>Probability of observing X or more given true rate is 5%</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>&lt;60 Years</td>
<td>1</td>
<td>15</td>
<td>7%</td>
<td>0.37</td>
<td>0.54</td>
</tr>
<tr>
<td></td>
<td>&gt;60 Years</td>
<td>1</td>
<td>35</td>
<td>3%</td>
<td>0.66</td>
<td>0.83</td>
</tr>
<tr>
<td></td>
<td>Total A</td>
<td>2</td>
<td>50</td>
<td>4%</td>
<td>0.44</td>
<td>0.72</td>
</tr>
<tr>
<td>B</td>
<td>&lt;60 Years</td>
<td>2</td>
<td>11</td>
<td>18%</td>
<td><strong>0.04</strong></td>
<td><strong>0.10</strong></td>
</tr>
<tr>
<td></td>
<td>&gt;60 Years</td>
<td>3</td>
<td>40</td>
<td>8%</td>
<td>0.12</td>
<td>0.32</td>
</tr>
<tr>
<td></td>
<td>Total B</td>
<td>5</td>
<td>51</td>
<td>10%</td>
<td><strong>0.02</strong></td>
<td><strong>0.11</strong></td>
</tr>
<tr>
<td>C</td>
<td>&lt;60 Years</td>
<td>1</td>
<td>20</td>
<td>5%</td>
<td>0.46</td>
<td>0.64</td>
</tr>
<tr>
<td></td>
<td>&gt;60 Years</td>
<td>0</td>
<td>30</td>
<td>0%</td>
<td>0.60</td>
<td>0.79</td>
</tr>
<tr>
<td></td>
<td>Total C</td>
<td>1</td>
<td>50</td>
<td>2%</td>
<td>0.78</td>
<td>0.92</td>
</tr>
</tbody>
</table>

sICH=symptomatic intracranial hemorrhage
Stopping rule: If the posterior probability that the sICH rate is greater than 3% >95%.

Bayesian. Assume a prior (3% is true) but with only a few subjects, e.g. 5.

Table 9 – Example of Monthly DSMB sICH Safety Table

<table>
<thead>
<tr>
<th>Subgroup</th>
<th>Number of Subjects with sICH</th>
<th>N</th>
<th>% of Subjects</th>
<th>Probability that sICH rate is &gt;3%*</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;60 Years</td>
<td>1</td>
<td>15</td>
<td>7%</td>
<td>0.63</td>
</tr>
<tr>
<td>&gt;60 Years</td>
<td>1</td>
<td>35</td>
<td>3%</td>
<td>0.36</td>
</tr>
<tr>
<td>Total A</td>
<td>2</td>
<td>50</td>
<td>4%</td>
<td>0.56</td>
</tr>
<tr>
<td>&lt;60 Years</td>
<td>3</td>
<td>11</td>
<td>27%</td>
<td>0.99</td>
</tr>
<tr>
<td>&gt;60 Years</td>
<td>2</td>
<td>40</td>
<td>5%</td>
<td>0.66</td>
</tr>
<tr>
<td>Total B</td>
<td>5</td>
<td>51</td>
<td>10%</td>
<td>0.98</td>
</tr>
<tr>
<td>&lt;60 Years</td>
<td>1</td>
<td>20</td>
<td>5%</td>
<td>0.55</td>
</tr>
<tr>
<td>&gt;60 Years</td>
<td>0</td>
<td>30</td>
<td>0%</td>
<td>0.04</td>
</tr>
<tr>
<td>Total C</td>
<td>1</td>
<td>50</td>
<td>2%</td>
<td>0.24</td>
</tr>
</tbody>
</table>

*Assuming a weighted beta (0.03*W, 0.97*W) prior with W = 5 subjects.
Signals of Harm?
Most Frequent On-Therapy Adverse Events Sorted by Risk Difference

Proportion

Risk Difference with 0.95 CI

Less Risk

More Risk

-0.2

-0.1

0.0

0.1

0.2

0.0

0.1

0.2

CHRONIC OBSTRUCTIVE AIRWAY
DYSPEPSIA
CHEST PAIN
BRONCHITIS
RHEUMATISM
MELEN
URINARY TRACT INFECTION
MYALGIA
COUGHING
RASH
HYPERKALEMIA
GASTROESOPHAGEAL REFLUX
INFECTION VIRAL
SINUSITIS
UPPER RESP TRACT INFECTION
RESPIRATORY DISORDER
BACK PAIN
INJURY
FATIGUE
FLATULENCE
HEADACHE
PAIN
HEMATURE
ANOREXIA
DIZZINESS
ARTHRALGIA
INSOMNIA
ABDOMINAL PAIN
VOMITING
DYSPEPSIA
DIARRHEA
NAUSEA

Treatment (N=&NA) ▲ Control (N=&NB)
Safety concern?
Volcano Plot

P-risk (Odds Ratio) Plot of Treatment Emergent Adverse Events at PT Level
Labs, vital signs, EKG: extremes

- Quantitative Diagnostic or Safety measurements (lab, vital signs, EKG) - examine extreme observations rather than mean trends.
  - Sample Quantiles (5th, 95th)
- Central Labs have reference ranges.
- proportion has safety measurements btw upper and lower limits
Lab Data Displayed as Continuous
Effect over Time

- Box and Whisker Plot (box-plot)
- Shift Table
- Heat Map
Shift Tables

- Once reference limits have been established, quantitative variables are often converted into categorical variables.
- E.g. Lab tests are often categorized as “High”, “Low”, “Normal” (In Range).
- Shift tables or contingency tables are often used to track baseline vs post baseline lab results.
### Example of Shift Table

<table>
<thead>
<tr>
<th>Labs</th>
<th>Tx</th>
<th>Baseline</th>
<th>Follow-up</th>
<th>1 month</th>
<th>3 month</th>
<th>6 month</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>%</td>
<td>N</td>
</tr>
<tr>
<td>ALBUMIN</td>
<td>A</td>
<td>Normal/In range</td>
<td>Normal/In range</td>
<td>381</td>
<td>91%</td>
<td>344</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Abnormal/Out of range</td>
<td>39</td>
<td>9%</td>
<td>29</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>420</td>
<td>100%</td>
<td>373</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Abnormal/Out of range</td>
<td>Normal/In range</td>
<td>31</td>
<td>31%</td>
<td>25</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Abnormal/Out of range</td>
<td>Abnormal/Out of range</td>
<td>70</td>
<td>69%</td>
<td>64</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>101</td>
<td>100%</td>
<td>89</td>
</tr>
<tr>
<td>B</td>
<td>Normal/In range</td>
<td>Normal/In range</td>
<td>Normal/In range</td>
<td>191</td>
<td>46%</td>
<td>180</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Abnormal/Out of range</td>
<td>227</td>
<td>54%</td>
<td>178</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>418</td>
<td>100%</td>
<td>358</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Abnormal/Out of range</td>
<td>Normal/In range</td>
<td>3</td>
<td>3%</td>
<td>5</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Abnormal/Out of range</td>
<td>Abnormal/Out of range</td>
<td>110</td>
<td>97%</td>
<td>100</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>113</td>
<td>100%</td>
<td>105</td>
</tr>
</tbody>
</table>
Heat Map

- Easy way to “make sense” of longitudinal, ordinal data, without summarizing data.
- Lab data is continuous, but ordinal may make more sense.
  - Actual value vs Normal/Abnormal
Example: LS-1
Creatine for Parkinson's Disease

- Stopping Rule > 2 creatinine only occurred in the creatine group
Unexpected Events
Sentinel Events

- Anticipated (Expected) AEs - can plan

- How to monitor unanticipated AEs
  - Depends on balance of risk to benefit
  - Depends on the severity of the AE
  - Sentinel event triggers a monitoring activity

- Eg: Childhood vaccine: single death early in trial.
  - Monitor # of administrations until $k^{th}$ event
  - Model distribution of time to event (add to SMP)
Why are Harms found late?

- Rare events
- Small sample size
- Exclude people likely to be harmed
- Avoid composites
  - MedDRA terms should be grouped.
- Use the wrong denominator
  - Persons at risk
  - Person time
  - Doses
  - ITT sample
Examples of Harm Found Late

- Short term studies for long-term use
  - Rofecoxib, celecoxib: *thrombotic events*
  - Diabetes drugs: *cardiovascular mortality*
  - Antipsychotics: *development of diabetes*
- Ignored early signals: ketek, troglitazone -*liver*
- Very rare event:
  - Tysabri: *progressive multifocal leukoencephalopathy*
- Never studied: Hormones: *heart attack, strokes*

Summary

- Know what is expected with drug/control
- Pre-specify AEs of importance
- Consider risk/benefit
- Group similar events/composites (collect uniformly)
- Be reasonable with multiple comparison
- Unexpected event(s) will prompt increased monitoring of near events (DSMB)
References

- Janet Wittes, PhD "Why are harms found late?" Biostatistics and FDA Regulation: Convergence of Science and Law, Cambridge MA, 20/May/2014
  http://www.fdli.org/docs/biostatistics/wittes.pdf?sfvrsn=0